



12 November 2015

ASX Limited
20 Bridge Street
Sydney NSW 2000

COMPANY ANNOUNCEMENTS

RESULTS OF THE ANNUAL GENERAL MEETING OF MEMBERS

In accordance with Listing Rule 3.13.2, Cellmid Limited (**ASX: CDY**) advises that the resolutions put to the Annual General Meeting of Shareholders held on Thursday 12 November 2015 were passed by the requisite majority.

All resolutions were passed without a poll on a show of hands.

Please find attached the information required pursuant to Section 251AA of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

End
Contact:
Maria Halasz
Managing Director and CEO
T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with two revenue generating businesses; a consumer health and a midkine division. The Company's consumer health division owns proprietary technologies and products around FGF5 inhibition, a novel mechanism for increasing hair growth and reducing hair loss. The midkine division is focused on developing drug candidates in oncology and nephropathy, while out-licensing diagnostics for a number of cancer indications. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.

DISCLOSURE OF PROXY VOTES

Annual General Meeting-Thursdays, 12 November 2015

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes in respect of which appointment specifies				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1. Adoption of the Company's Remuneration Report	S	131,949,360	127,812,560	4,136,800	1,277,358	0	n/a	n/a	n/a
2. Re - election of Dr. David King as Non-Executive Director	S	144,003,337	135,023,137	3,004,500	493,381	5,975,700	n/a	n/a	n/a
3. Approval for the issue of 4,000,000 options at \$0.06 with a term of three years to Director Dr. David King	S	143,725,837	133,300,560	4,465,577	770,881	5,959,700	n/a	n/a	n/a
4. Approval for the issue of 2,000,000 options at \$0.06 with a term of three years to Director Mr. Bruce Gordon	S	143,725,837	133,300,560	4,465,577	23,270,881	5,959,700	n/a	n/a	n/a
5. Approval for the issue of 2,000,000 options at \$0.06 with a term of three years to Director Dr. Fintan Walton	S	143,925,837	133,360,560	4,605,577	23,070,881	5,959,700	n/a	n/a	n/a